Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03048604
Recruitment Status : Completed
First Posted : February 9, 2017
Last Update Posted : October 11, 2021
Information provided by (Responsible Party):
Nyxoah S.A.

Brief Summary:
The study is designed as a prospective, open-label, multicentre, non-randomized, single arm treatment study to assess the safety, performance and initial efficacy trends of the GenioTM System in patients with Obstructive Sleep Apnoea (OSA).

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea of Adult Device: Genio(TM) bilateral hypoglossal nerve stimulation system Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre, Prospective, Open-label, Non-randomized, Single Arm Treatment Study to Assess the Safety, Performance and Initial Efficacy Trends of the Genio(TM) Bilateral Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnoea.
Actual Study Start Date : March 30, 2017
Actual Primary Completion Date : September 10, 2018
Actual Study Completion Date : September 10, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Experimental: Genio(TM) system therapy Device: Genio(TM) bilateral hypoglossal nerve stimulation system
Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.

Primary Outcome Measures :
  1. Safety (Incidence of serious device-related adverse events) [ Time Frame: 6-months post implantation ]
    Incidence of serious device-related adverse events

  2. Performance [ Time Frame: 6-months post implantation ]
    Change from baseline to 6-month post implantation in the apnoea-hypopnea index (AHI)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Body mass index ≤32 kg/m2
  • Patients who do not tolerate or do not accept positive airway pressure (PAP) treatments.
  • Obstructive apnoea-hypopnea index (AHI) of 20-60 events/hour

Main Exclusion Criteria:

  • Unable or incapable of providing informed written consent
  • Unwilling or incapable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires
  • Significant co-morbidities making the patient unable or inappropriate to participate in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03048604

Layout table for location information
Australia, Perth
Hollywood Private UWA Centre for Sleep Science Facility
Nedlands, Perth, Australia
La Pitié Salpêtrière - Paris
Paris, France
United Kingdom
Royal National Throat, Nose and Ear Hospital - London
London, United Kingdom
Sponsors and Collaborators
Nyxoah S.A.
Layout table for investigator information
Principal Investigator: Valérie Attali, Dr. La Pitié Salpêtrière, Paris
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Nyxoah S.A. Identifier: NCT03048604    
Other Study ID Numbers: BLAST OSA
First Posted: February 9, 2017    Key Record Dates
Last Update Posted: October 11, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases